New combo attack on rectal cancer: chemo plus targeted surgery shows promise
NCT ID NCT06048146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 180 people with rectal cancer that had spread to lymph nodes in the pelvis. One group received a three-drug chemotherapy regimen (FOLFOXIRI) followed by surgery to remove the affected lymph nodes. The other group got standard chemoradiotherapy before surgery. The goal was to see if the new approach improves how long people live without the cancer coming back. The trial is complete, and results will help determine if this more intensive treatment is worth the extra side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FOLFOXIRI (irinotecan, oxaliplatin, 5-fluorouracil) and lateral lymph node dissection
- What this could lead to
- If successful, this approach could improve survival and reduce cancer recurrence for people with rectal cancer that has spread to nearby lymph nodes.
- What could go wrong
- This is a completed study with 180 participants, but results are not yet widely confirmed. The three-drug chemo regimen has higher side effects, and the surgery adds risks. Further research is needed to see if it truly beats standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
180 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-70 years old, gender is not limited; * The clinical stage based on magnetic resonance imaging (MRI) is cT1-4aN+M0 (according to AJCC Cancer Staging Manual, 8th Edition, 2018). * Meet the criteria for lateral lymph node metastasis (lymph node short diameter ≥7mm, or lymph node short diameter ≥5cm with uneven internal signals and no chemical shift effect, or irregular boundaries); * The primary tumor was located in the rectum (hard tube proctoscopy indicated that the lower margin of the lesion was less than 10cm from the anus); * Kastler score ≥70, ECOG score 0 or 1; * Meet the following laboratory diagnostic indicators: hemoglobin ≥100g/L, white blood cells ≥3.5×109 /L, neutrophil ≥1.5×109/L, platelet ≥100×109/L; Creatinine ≤1.5× upper limit of normal (UNL); Urea nitrogen (BUN) ≤1.5 upper limit of normal (UNL) alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2.5×UNL, alkaline phosphatase (ALP) ≤2.5×UNL, total bilirubin (Tbil) ≤2.5×UNL; Urinary protein (-); Clotting time is normal. * Patients with primary locally advanced rectal cancer required that they had not received surgery, radiotherapy, chemotherapy or other antitumor therapy from diagnosis to enrollment; No previous pelvic radiation; * Subjects voluntarily join the study and sign the informed consent. Exclusion Criteria: * A history of malignancy at other sites, excluding curable non-melanic skin cancer and carcinoma in situ of the cervix; * Unable to complete MRI; * Preoperative examination indicated the need for combined organ resection; * Allergic to 5-Fu and platinum drugs; Inability to swallow oral medications; * The patient is under thrombolytic or anticoagulant therapy, has bleeding diathesis or coagulation dysfunction, or has occurred in the past year Aneurysm, stroke, transient ischemic attack, arteriovenous malformation; * After renal history, urine test found proteinuria or clinical renal function was obviously abnormal; * History of digestive tract fistula, perforation or severe ulcer; * Active infection is present; Clinically significant cardiac disease (e.g., uncontrolled hypertension (160/110) mm Hg blood pressure, any history of myocardial infarction, unstable angina), NYHA class Ⅱ congestive heart failure, unstable symptomatic arrhythmias, or class II peripheral vascular disease. Myocardial infarction and cerebrovascular accident occurred within 6 months before enrollment; * Participating in other clinical trials currently or within 4 weeks prior to enrollment; * long-term adverse drug history, drug addiction history of mental disorders; * Other cases where the examiner considers from the registration study that there are good reasons for non-conformity: if there are potential inconsistencies with the clinical protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer of rectum and anus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early oral cancer patients skip neck surgery?
- Experimental drug velzatinib offered to GIST patients who have run out of options
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Muscle loss may predict who struggles after cancer surgery
- Radioactive antibody aims to light up hidden solid tumors
- Can a platform trial match the right drug combo to each tumor?